drugset / Trial / NCT01079013

Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

NCT01079013

Phase 2 Unknown 40 enrolled Sheba Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.

Timeline

Start
2010-03
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Treosulfan Small molecule 12000 mg/m2 Intravenous